molecules of the month


DNA-PK-selective kinase inhibitor

oral efficacy in xenograft radiation models

undisclosed screening and optimization

Mol. Cancer Ther., Mar. 27, 2020

Merck KGaA, Darmstadt, DE

1 min read

M3814 (Merck KGaA oral DNA-PK selective kinase inhibitor)

request a trial

You don’t have time to read everything, but you can’t afford to fall behind.

Drug Hunter Premium is drug discovery, distilled, so you can quickly catch up and make informed decisions based on industry examples.

Get ahead now by requesting a trial.

already a member? log in: